Copyright
©The Author(s) 2024.
World J Clin Cases. Aug 26, 2024; 12(24): 5468-5472
Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5468
Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5468
Figure 1 Colonoscopy.
Pre-biologic. Ulcerative colitis with friability and ulcers, Mayo endoscopic score 2. A: Transition zone in the transverse colon; B: Sigmoid colon.
Figure 2 Colonoscopy.
Pre-Tofacitinib. Improvement, but still presenting ulcerative colitis with patchy areas of friability and ulcers, Mayo endoscopic score 2. A: Transition zone in the transverse colon; B: Sigmoid colon.
Figure 3 Colonoscopy.
Maintenance therapy with infliximab, three years after tofacitinib was withdrawn. Scarred mucosa, Mayo endoscopic score 0. A: Transition zone in the transverse colon; B: Sigmoid colon.
- Citation: Soldera J. Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis. World J Clin Cases 2024; 12(24): 5468-5472
- URL: https://www.wjgnet.com/2307-8960/full/v12/i24/5468.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i24.5468